Plasma KIM-1 levels may be a useful, noninvasive biomarker for risk prognostication in metastatic RCC. Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with ...
The clinical efficacy of enfortumab vedotin plus pembrolizumab in real-world patients is compatible with that of the phase 3 EV-302 clinical trial. Treatment with enfortumab vedotin plus ...
Amid a rapidly evolving landscape in the treatment of muscle-invasive bladder cancer (MIBC), new findings presented at the ...
A recent study explored the association between rectal spacer use and the US county-level prevalence of erectile dysfunction.
According to investigators, there is no validated PSA-based endpoint to compare oncologic outcomes after radical prostatectomy and radiation therapy for localized prostate cancer.
The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.
Lutetium 177-PSMA-617 is an appropriate alternative to cabazitaxel in patients with metastatic castration-resistant prostate cancer, resulting in better progression-free survival. Greater survival ...
Opioid prescriptions in the emergency department linked to small increases in hospital admission and subsequent opioid prescription use ...
Investigators assessed whether MRI alone can identify all cases of Gleason grade group 2 or higher disease in patients on ...
Burnout in US oncologists has increased over the past 10 years, according to results of 2 surveys. 1 Researchers compared results of a 2023 survey of 328 oncologists to results of a 2013 survey of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback